公开(公告)号：US20240287445A1

公开(公告)日：2024-08-29

申请号：US18549090

申请日：2020-10-13

Applicant: PLANT PROTECTION RESEARCH INSTITUTE OF GUANGDONG ACADEMY OF AGRICULTURAL SCIENCES ,  GUANGDONG BRANCH OF CHINA TOBACCO GENERAL CO., LTD.

Inventor： Qiyun YANG ,  Birun LIN ,  Zheng LU ,  Jingxin ZHANG ,  Dayuan SUN ,  Yonghua LV ,  Huifang SHEN ,  Xiaoming PU

IPC: C12N1/20 ,  A01N43/24 ,  A01N63/28 ,  A01P3/00 ,  C12N3/00 ,  C12P17/08 ,  C12R1/48

CPC classification number: C12N1/20 ,  A01N43/24 ,  A01N63/28 ,  A01P3/00 ,  C12N3/00 ,  C12P17/08 ,  C12R2001/48

Abstract: A Streptomyces antibioticus PPI-16 with the accession number of GDMCC NO: 60970. Active compounds produced thereby can inhibit multiple pathogenic fungi, including Colletrichum orbiculare, Colletotrichum capsica, Tobacco anthracnose, and Candida albicans.

公开(公告)号：US11851692B2

公开(公告)日：2023-12-26

申请号：US18127674

申请日：2023-03-29

Applicant: Ningbo University

Inventor： Lijian Ding ,  Shan He ,  Wenhao Li ,  Weiyan Zhang ,  Yingying Wei

IPC: C12P17/08 ,  C07D321/00

CPC classification number: C12P17/08 ,  C07D321/00

Abstract: Disclosed are an antimycin compound and a preparation method and use thereof. The preparation method comprises: fermenting a marine actinomycete (Streptomyces sp.4-7) with a preservation number CCTCCNO: M2020953 to obtain a fermented product and soaking and extracting the fermented product with ethyl acetate to obtain a crude extract; and carrying out separation and purification by normal-phase silica gel column chromatography, reversed-phase MPLC, and semi-preparative reversed-phase high-performance liquid chromatography. The invention has the advantages of resistance against Botrytis cinerea and Penicillium citrinum.

公开(公告)号：US20220387295A1

公开(公告)日：2022-12-08

申请号：US17427069

申请日：2020-01-31

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Hee Sik KIM ,  Dae Hyun CHO ,  Jin A HEO ,  U Rim KIM ,  Su Bin PARK

IPC: A61K8/9722 ,  C12N1/12 ,  C12P17/08 ,  A61Q19/08 ,  A61K8/49

Abstract: The present invention relates to novel microalgae with high productivity of loliolide, in which the Scenedesmus sp. HS4 of the present invention can be used as a biological resource to produce loliolide due to its high biomass productivity and high loliolide content, and can be used as a pharmaceutical composition or cosmetic composition which requires loliolide derived from Scenedesmus sp. HS4.

公开(公告)号：US20220235385A1

公开(公告)日：2022-07-28

申请号：US17605196

申请日：2020-04-24

Applicant: Genomatica, Inc.

Inventor： Amit M. Shah ,  Harish Nagarajan

IPC: C12P13/00 ,  C12P17/08 ,  C12P17/10 ,  C12P7/18 ,  C12P7/44 ,  C12P7/62 ,  C12N9/02

Abstract: Disclosed are biosynthetic methods and engineered microorganism that enhance or improve the biosynthesis of hexamethylenediamine, caproic acid or caprolactam. The engineered microorganisms include selected aldehyde dehydrogenase activity.

公开(公告)号：US20190309331A1

公开(公告)日：2019-10-10

申请号：US16423402

申请日：2019-05-28

Applicant: The Regents of the University of California

Inventor： Robert W. Haushalter ,  Jay D. Keasling

IPC: C12P7/44 ,  C12P17/08 ,  C12N9/10 ,  C12N9/16

Abstract: The present invention provides for a genetically modified host cell and related methods and materials for the biocatalytic production of an α,ω-dicarboxylic acids (DCAs) and/or mono-methyl ester derivatives of dicarboxylic acids (DCAMMEs).

公开(公告)号：US20180298352A1

公开(公告)日：2018-10-18

申请号：US15524643

申请日：2015-11-04

Applicant: Erber Aktiengesellschaft

Inventor： Juan Antonio TORRES ACOSTA ,  Gerhard ADAM ,  Elisavet KUNZ-VEKIRU ,  Wulf-Dieter Moll ,  Rudolf MITTERBAUER ,  Clemens SCHMEITZL

IPC: C12N9/02 ,  C12P17/08 ,  C12N15/81

Abstract: The invention relates to a polypeptide for the enzymatic detoxification of zearalenone, said polypeptide being a monooxygenase which converts the keto group in position 7 of zearalenone into an ester group, the monooxygenase in particular being an amino acid sequence selected from the group comprising sequence ID No. 1, 2 and 3 or a functional variant thereof. The functional variant and at least one of the amino acid sequences has a sequence identity of at least 60%, preferably at least 70%, more preferably at least 80% and most preferably 90%,

公开(公告)号：US20160355855A1

公开(公告)日：2016-12-08

申请号：US14995069

申请日：2016-01-13

Applicant: Genomatica, Inc.

Inventor： Anthony P. BURGARD ,  Robin E. OSTERHOUT ,  Priti PHARKYA ,  Mark J. BURK

IPC: C12P17/08 ,  C08G63/08 ,  C12N15/52 ,  C12N5/00 ,  C07D313/04

CPC classification number: C12P17/08 ,  C07D313/04 ,  C08G18/4277 ,  C08G63/08 ,  C12N5/0018 ,  C12N15/52 ,  C12N15/63 ,  C12N15/70 ,  C12P17/02

Abstract: The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

公开(公告)号：US08940509B2

公开(公告)日：2015-01-27

申请号：US13668117

申请日：2012-11-02

Applicant: Anthony P. Burgard ,  Robin E. Osterhout ,  Priti Pharkya ,  Mark J. Burk

Inventor： Anthony P. Burgard ,  Robin E. Osterhout ,  Priti Pharkya ,  Mark J. Burk

IPC: C07D313/04 ,  C12N15/63 ,  C12P17/02 ,  C12N5/00 ,  C08G18/42 ,  C12P17/08

CPC classification number: C12P17/08 ,  C07D313/04 ,  C08G18/4277 ,  C08G63/08 ,  C12N5/0018 ,  C12N15/52 ,  C12N15/63 ,  C12N15/70 ,  C12P17/02

Abstract: The invention provides non-naturally occurring microbial organisms containing caprolactone pathways having at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce caprolactone. The invention additionally provides methods of using such microbial organisms to produce caprolactone by culturing a non-naturally occurring microbial organism containing caprolactone pathways as described herein under conditions and for a sufficient period of time to produce caprolactone.

Abstract translation: 本发明提供了非天然存在的含有己内酯途径的微生物，其具有至少一种编码丁二烯途径酶的外源核酸，其表达量足以产生己内酯。 本发明另外提供了使用这种微生物生物体来制备己内酯的方法，该方法是在条件和足够的时间内培养含本文所述的己内酯途径的非天然存在的微生物生物产生己内酯。

公开(公告)号：US20120071549A1

公开(公告)日：2012-03-22

申请号：US13321112

申请日：2010-05-24

Applicant: Young-Hoon Ji ,  Dong-Hee Kim ,  Jae-Seon Kang ,  Chun-Gyu Kim ,  Sung-Uk Chung ,  Sung-Woo Hwang ,  Kyung-Ran Kang

Inventor： Young-Hoon Ji ,  Dong-Hee Kim ,  Jae-Seon Kang ,  Chun-Gyu Kim ,  Sung-Uk Chung ,  Sung-Woo Hwang ,  Kyung-Ran Kang

IPC: A61K31/365 ,  C12P17/08 ,  A61P29/00 ,  C07D313/00

CPC classification number: A61K31/335 ,  A61K31/365

Abstract: The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by the Bacillus polyfermenticus KJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.

Abstract translation: 本发明涉及由新生芽孢杆菌（Bacillus polyfermenticus）KJS-2（KCCM10769P）的芽孢杆菌菌株生产的大多数内消旋用途的大多数乳糖素A，7-O-丙二酰基大内酰胺素A和7-O-琥珀酰基大内酰胺素A ）。 证实本发明提供的大内酰胺化合物能够大大抑制与形成炎症介质相关的蛋白质的诱导型一氧化氮合成酶（iNOS）和环氧合酶-2（COX-2）的表达和形成，并因此抑制 形成一氧化氮（NO）和作为蛋白质代谢物的前列腺素E2（PGE2）。 此外，本发明提供的大多数内消旋化合物被证实在抑制肿瘤坏死因子-α（TNF-α），白细胞介素-1和bgr的形成方面具有优异的效果。 （IL-1和bgr），白介素-6（IL-6）和粒细胞巨噬细胞集落刺激因子（GM-CSF），其是促炎细胞因子。 因此，本发明的由芽孢杆菌属多发性支原体KJS-2株产生的大分子内酯化合物可提供优异的抗炎剂。

公开(公告)号：US20110034528A1

公开(公告)日：2011-02-10

申请号：US12918197

申请日：2009-02-19

Applicant: Klaus Gerth ,  Heinrich Steinmetz ,  Gerhard Höfle

Inventor： Klaus Gerth ,  Heinrich Steinmetz ,  Gerhard Höfle

IPC: A61K31/4184 ,  C07D313/00 ,  C07C59/54 ,  C07C59/72 ,  C07C229/60 ,  C07C229/56 ,  C07D333/24 ,  C07D307/54 ,  C07C309/61 ,  C07D235/30 ,  A61K31/335 ,  A61K31/192 ,  A61K31/196 ,  A61K31/381 ,  A61K31/34 ,  A61P31/04 ,  C12P17/00 ,  C12P17/08 ,  C12P17/04 ,  C12P13/00 ,  C12P11/00 ,  C12P7/42 ,  C12N1/20

CPC classification number: C07C59/72 ,  C07C59/54 ,  C07C229/56 ,  C07C2602/08 ,  C07D313/00 ,  C12P7/42 ,  C12P13/001 ,  C12P17/08

Abstract: The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).

Abstract translation: 本发明描述了Elansolids，一类新的式（I）的新型抗菌化合物。